First COVID-19 Trial Success For Roche’s Actemra, But No Sign It Saves Lives
Trial Focused On Hispanic, Black And Native Americans
A composite endpoint conceals Actemra’s lack of mortality benefit – while life-saving dexamethasone gets EMA endorsement.
You may also be interested in...
Analysts called the interim data from a Phase II study of LY-CoV555 mixed, but Lilly insists that it has demonstrated a therapeutic role for neutralizing antibodies in fighting the novel coronavirus.
Disappointment as Roche/Chugai antibody tocilizumab misses most endpoints.
Many clinicians doubt that aducanumab can really help slow the decline in Alzheimer’s patients – but US FDA could offer it the benefit of the doubt.